TXNRD1 and cancer: The discovery of EF24-TrxR1 interaction provides deep insight into the understanding of how EF24 acts in vivo and this novel targeting mechanism may lead to the development of potent small-molecule TrxR1 inhibitors as potential cancer chemotherapeutic agents.